Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average of $1.69

Compugen Ltd. (NASDAQ:CGEN)’s stock price passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.69 and traded as high as $1.96. Compugen shares last traded at $1.89, with a volume of 202,009 shares trading hands.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Compugen from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th.

Compugen Trading Down 0.5 %

The stock has a market capitalization of $163.71 million, a P/E ratio of -8.59 and a beta of 2.64. The stock has a 50 day moving average of $2.45 and a 200-day moving average of $1.69.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings results on Tuesday, March 5th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.01. The business had revenue of $33.46 million for the quarter, compared to the consensus estimate of $60.00 million. Research analysts anticipate that Compugen Ltd. will post 0.02 EPS for the current year.

Institutional Investors Weigh In On Compugen

Institutional investors and hedge funds have recently bought and sold shares of the company. Tocqueville Asset Management L.P. bought a new stake in Compugen during the 3rd quarter valued at $71,000. Kingsview Wealth Management LLC bought a new stake in Compugen during the 3rd quarter valued at $78,000. Finally, Silverarc Capital Management LLC raised its position in Compugen by 6.1% during the 3rd quarter. Silverarc Capital Management LLC now owns 350,188 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 20,000 shares in the last quarter. 12.22% of the stock is owned by institutional investors.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.